ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals’ drug Amvuttra to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and potentially fatal heart condition. The green light positions Alnylam to challenge Pfizer’s blockbuster drug Vyndaqel in a market projected to exceed $11 billion by 2032, according to Global Market Insights.
Amvuttra, chemically known as vutrisiran, was initially approved in 2022 for ATTR-related nerve damage. This expanded approval makes it the first therapy available to treat both nerve and cardiac manifestations of the disease. Unlike Vyndaqel and BridgeBio’s Attruby, which stabilize faulty transthyretin proteins, Amvuttra works by reducing production of the disease-causing protein at its source.
Alnylam aims to leverage this milestone to reach profitability and fund future innovations. “It’s going to help us get to profitability and help us invest in the next generation of molecules,” said Chief Medical Officer Pushkal Garg.
Pricing will be critical in gaining market share. For nerve damage, Amvuttra costs $119,351 per prefilled syringe and is administered quarterly. Alnylam confirmed the same price for treating ATTR-CM. In comparison, Attruby is priced at $18,759.12 per 28-day supply, while Vyndaqel costs approximately $268,000 annually.
Despite being an injectable therapy in a market with oral options, analysts project Amvuttra could generate nearly $5 billion in sales by 2029, according to LSEG. Alnylam will need to focus on strategic commercialization to attract patients to its new treatment.
Following the FDA announcement, Alnylam’s shares were temporarily halted in after-hours trading.
